Biotech · Public company · San Diego, CA, US
Halozyme Therapeutics, Inc.
Ticker HALO · SEC CIK 0001159036
Track this companyFree. Adds Halozyme Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials183 recruiting or active
Pipeline programs37From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline37
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)Phase 3 · Pancreatic Ductal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 3 · Pancreatic Ductal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- nab-PaclitaxelPhase 3 · Pancreatic Ductal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Testosterone enanthatePhase 3 · Hypogonadism, MaleClinicalTrials.gov · fetched Nov 12, 2026
- ChemophasePhase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- EnoxaparinPhase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- HumalogPhase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Humulin-RPhase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Insulin aspartPhase 2 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Insulin glarginePhase 2 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Insulin glulisinePhase 2 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Insulin lisproPhase 2 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Liquid mealPhase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Mitomycin CPhase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxelPhase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- PEGPH20Phase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- recombinant human hyaluronidase PH20Phase 2 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Recombinant human hyaluronidase PH20 (rHuPH20)Phase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- rHuPH20Phase 2 · Dermatitis, Allergic ContactClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Cholangiocarcinoma Non-resectableClinicalTrials.gov · fetched Nov 12, 2026
- CISPhase 1 · Cholangiocarcinoma Non-resectableClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 1 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- GEMPhase 1 · Cholangiocarcinoma Non-resectableClinicalTrials.gov · fetched Nov 12, 2026
- HumalogPhase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Humulin-RPhase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- PEGPH20Phase 1 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PEGPH20Phase 1 · Cholangiocarcinoma Non-resectableClinicalTrials.gov · fetched Nov 12, 2026
- PEGylated recombinant human hyaluronidase PH20Phase 1 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Recombinant human hyaluronidase PH20 (rHuPH20)Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Insulin aspartType 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Insulin lisproType 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Rapid Acting insulin with pre-treatment of rHuPH20Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Recombinant human hyaluronidase PH20Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Sham InjectionType 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials18
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismPHASE3 · RECRUITING · started Mar 7, 2025ClinicalTrials.gov NCT06689085 · fetched Nov 12, 2026
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 6, 2023ClinicalTrials.gov NCT05625399 · fetched Nov 12, 2026
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)PHASE1_PHASE2 · TERMINATED · started Oct 13, 2017ClinicalTrials.gov NCT03281369 · fetched Nov 12, 2026
- Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaPHASE1 · TERMINATED · started Oct 2, 2017ClinicalTrials.gov NCT03267940 · fetched Nov 12, 2026
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic AdenocarcinomaNA · ACTIVE_NOT_RECRUITING · started Oct 1, 2016ClinicalTrials.gov NCT02921022 · fetched Nov 12, 2026
- Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)PHASE1_PHASE2 · TERMINATED · started Jul 13, 2016ClinicalTrials.gov NCT02753595 · fetched Nov 12, 2026
- A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaPHASE3 · TERMINATED · started Mar 14, 2016ClinicalTrials.gov NCT02715804 · fetched Nov 12, 2026
- A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsPHASE1 · COMPLETED · started Oct 22, 2015ClinicalTrials.gov NCT02563548 · fetched Nov 12, 2026
- A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLCPHASE1 · TERMINATED · started Feb 10, 2015ClinicalTrials.gov NCT02346370 · fetched Nov 12, 2026
- A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)PHASE4 · COMPLETED · started Oct 3, 2013ClinicalTrials.gov NCT03662334 · fetched Nov 12, 2026
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerPHASE2 · COMPLETED · started May 14, 2013ClinicalTrials.gov NCT01839487 · fetched Nov 12, 2026
- Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human HyaluronidasePHASE4 · COMPLETED · started Dec 1, 2011ClinicalTrials.gov NCT01526733 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human HyaluronidasePHASE2 · COMPLETED · started Sep 12, 2011ClinicalTrials.gov NCT01426763 · fetched Nov 12, 2026
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusPHASE2 · COMPLETED · started Aug 1, 2010ClinicalTrials.gov NCT01194245 · fetched Nov 12, 2026
- Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact DermatitisPHASE2 · COMPLETED · started Jun 23, 2009ClinicalTrials.gov NCT00928447 · fetched Nov 12, 2026
- Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes MellitusPHASE2 · COMPLETED · started Oct 1, 2008ClinicalTrials.gov NCT00774800 · fetched Nov 12, 2026
- Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20PHASE1 · COMPLETED · started Dec 1, 2007ClinicalTrials.gov NCT00705536 · fetched Nov 12, 2026
- Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerPHASE1_PHASE2 · COMPLETED · started Mar 30, 2006ClinicalTrials.gov NCT00318643 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026